Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD7

CD7

Brief Information

Name:T-cell antigen CD7
Target Synonym:T-cell antigen CD7,GP40,CD7,TP41,CD7 Molecule,T-Cell Leukemia Antigen,T-Cell Surface Antigen Leu-9,CD7 Antigen (P41),P41 Protein,CD7 Antigen,LEU-9,Tp40,Antigens, CD7
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD7-HP2H6-Cell-based assay
 CD7 CAR_T

5e5 of anti-CD7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HP2H6) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

CD7-H82F3-ELISA
Biotinylated Human CD7, Fc,AvitagBiotinylated Human CD7, Fc,Avitag (Cat. No. CD7-H82F3) ELISA bioactivity

Immobilized Biotinylated Human CD7, Fc,Avitag (Cat. No. CD7-H82F3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD7 antibody, Mouse IgG1 with a linear range of 1-2 ng/mL (QC tested).

CD7-H82F3-MALS-HPLC
Biotinylated Human CD7, Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human CD7, Fc,Avitag(Cat. No. CD7-H82F3) is more than 90% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human CD7, Fc,AvitagBiotinylated Human CD7, Fc,Avitag (Cat. No. CD7-H82F3) ELISA bioactivity

Immobilized Biotinylated Human CD7, Fc,Avitag (Cat. No. CD7-H82F3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD7 antibody, Mouse IgG1 with a linear range of 1-2 ng/mL (QC tested).

Synonym Name

CD7,GP40,TP41,LEU-9,Tp40

Background

T-cell antigen CD7 (CD7) is also known as GP40, LEU-9, TP41 and Tp40. CD7 is a protein that in humans is encoded by the CD7 gene, this gene encodes a transmembrane protein which is a member of the immunoglobulin superfamily. CD7 has been shown to interact with PIK3R1. This protein is found on thymocytes and mature T cells. It plays an essential role in T-cell interactions and also in T-cell/B-cell interaction during early lymphoid development.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GC-027 GC-027 Phase 1 Clinical Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy GC-197 Phase 2 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD7 CAR-T cell Therapy (Shanghai General Hospital) Phase 1 Clinical Shanghai General Hospital Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell Details
PA3-17 PA3-17; PA-3-17; PA3-17 (autologous) Phase 1 Clinical Persongen Anke Cell Technology Co Ltd, Persongen Biotherapeutics (Suzhou) Co Ltd Hematologic Neoplasms; Lymphoma Details
SenL-T7 CAR T Cells (Hebei Senlang Biological) Senl-T7; Senl-T-7; SENL-101 Clinical Hebei Senlang Biological Technology Co Ltd Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
This CAR-T-7 cells therapy This CAR-T-7 cells Fundamenta Therapeutics Ltd Details
GC-502 GC-502 Details
Anti-CD7 universal CAR-T cell therapy (Xinqiao Hospital) Phase 1 Clinical Xinqiao Hospital, Army Medical University Lymphoma, T-Cell; Leukemia, T-Cell Details
CD7-CAR-T cell therapy (PersonGen Biomedicine) Phase 2 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd, The First Affiliated Hospital Of Zhengzhou University Leukemia; Enteropathy-Associated T-Cell Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic Details
CAR7-T Cell Therapy (Beijing Gaobo Biotechnology Co Ltd) Phase 1 Clinical Wuhan Union Hospital Lymphoma, T-Cell; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Humanized CD7 CAR-T cells Phase 2 Clinical The First Affiliated Hospital Of Soochow University Lymphoma, T-Cell Details
CD7 CAR-T cell therapy (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD7 CAR T-cell therapy (Yake Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Still's Disease, Adult-Onset; Leukemia; Dermatomyositis; Autoimmune Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Colitis, Ulcerative; Lymphoma; Crohn Disease Details
Anti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics) BT-007 Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd, Bioceltech Therapeutics Ltd Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
WU-CART-007 WU-CART-007 Phase 2 Clinical Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Leukemia-Lymphoma, Adult T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndrome; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Mycosis Fungoides Details
CD7 CARvac T cell therapy Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Hematologic Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
CD7 targeted CAR-γδ T cells therapy(Persongen Bio) Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Neoplasms; Leukemia, B-Cell Details
RD13-01 RD13-01; CTD-401 Clinical Zhejiang University, Nanjing Bioheng Biotech Co Ltd Hematologic Neoplasms Details
Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate HENO-3; SPV-T3a Phase 3 Clinical Xenikos Bv Graft vs Host Disease Details
BEAM-201 BEAM-201 Phase 1 Clinical Beam Therapeutics Inc Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message